Ebos lifted profit 21% in FY22 but analysts are asking how long it can last

Ebos lifted profit 21% in FY22 but analysts are asking how long it can last
Chief executive John Cullity said covid could be a tailwind or a headwind by the end of FY23. (Photo: Ebos)
Dan Brunskill
Ebos Group’s annual revenue has climbed above A$10 billion (NZ$11.15b) as the pandemic has increased demand for pharmaceutical products, but analysts are asking if that trend could reverse.  The healthcare and animal products company has been a beneficiary of the covid-19 pandemic, growing its revenue from A$8.7b in 2020 to A$10.7b in 2022.This year alone it grew revenue by 16.6%, underlying earnings by 19% and underlying net profit by 21.3% to A$228.2 million.Not all the growth has been driven by the pandemic however, Forsyth Barr r...

More Markets

Employment data dominates quiet day on NZ sharemarket
Markets

Employment data dominates quiet day on NZ sharemarket

The NZ sharemarket was down with no real trend driving the change.

Sharesies founders sell down
Markets

Sharesies founders sell down

Global tech investor Rahul Mehta appears in Companies Office filings for the first time.

Fletcher’s home consenting has tanked: Macquarie
Property

Fletcher’s home consenting has tanked: Macquarie

Building giant’s land sell-off may deepen residential gloom, analysts say.